4 completed, 3 recruiting, 2 not yet recruiting, 1 terminated. 5 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow Nasopharynx Cancer: new trials by email Literature Review of Nasopharynx Cancer trials Research Report on Nasopharynx Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma Cemiplimab, Fianlimab - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 1 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2026-09-01 | 2026-08-11 |
| GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC GEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy - Nasopharynx Cancer | Phase 2 | Not yet recruiting | Zhejiang Cancer Hospital | 41 | 2024-09-30 | 2024-09-25 |
| U87 CAR-T in Patients With Advanced Head and Neck Tumors U87 autologous CAR T-cell - Nasopharynx Cancer, Head and Neck Cancer | Phase 1 | Recruiting | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 20 | 2024-09-20 | 2024-09-26 |
| Nivolumab in Children and Adults With Nasopharyngeal Carcinoma Nivolumab, Cisplatin, 5-Fluorouracil - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 2 | Recruiting | German Society for Pediatric Oncology and Hematology GPOH gGmbH | 57 | 2023-01-10 | 2024-05-16 |
| The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers observation - Head and Neck Cancer, Nasopharynx Cancer | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 13600 | 2022-05-31 | 2026-04-03 | |
| Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma Nab-paclitaxel, Cisplatin and Fluorouracil, concurrent chemoradiotherapy - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 2 | Completed | Guangxi Medical University | 60 | 2019-03-28 | 2025-12-11 |
| 3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma 3DV+TPS/VARIAN, TPS / VARIAN, 3DV + TPS / Domestic Accelerator - Nasopharynx Cancer, Radiotherapy | Not applicable | Completed | Xinqiao Hospital of Chongqing | 100 | 2018-12-01 | 2024-02-23 |
| Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Pembrolizumab, Cetuximab - HNSCC, Lip SCC | Phase 2 | Completed | University of California, San Diego | 78 | 2017-03-28 | 2026-10-01 |
| Adaptive Radiotherapy for Head and Neck Cancer Adaptive Radiotherapy - Head and Neck Cancer, Paranasal Sinus Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 64 | 2017-03-15 | 2021-10-26 |
| Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx Nasopharynx Cancer | Terminated | University of Florida | 9 | 2008-06-01 | 2017-02-10 |
Nasopharyngeal Neoplasms (10) · Head and Neck Neoplasms (4) · Nasopharyngeal Carcinoma (3) · Hypopharyngeal Neoplasms (2) · Laryngeal Neoplasms (2) · Mouth Neoplasms (2) · Oropharyngeal Neoplasms (2) · Paranasal Sinus Neoplasms (2) · Neoplasm Metastasis (1) · Recurrence (1) · Salivary Gland Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Nasopharyngeal Diseases (10) · Neoplasms (10) · Neoplasms by Site (10) · Otorhinolaryngologic Diseases (10) · Otorhinolaryngologic Neoplasms (10) · Pharyngeal Diseases (10) · Pharyngeal Neoplasms (10) · Stomatognathic Diseases (10) · Head and Neck Neoplasms (6) · Carcinoma (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Mouth Diseases (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3)
Cisplatin (2) · Fluorouracil (2) · Gemcitabine (2) · 130-nm albumin-bound paclitaxel (1) · Cetuximab (1) · Chemoradiotherapy (1) · Endostatins (1) · Interferon beta-1a (1) · Nivolumab (1) · Observation (1) · Patient Reported Outcome Measures (1) · Radiotherapy (1) · cemiplimab (1) · pembrolizumab (1)
Memorial Sloan Kettering Cancer Center (2) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · German Society for Pediatric Oncology and Hematology GPOH gGmbH (1) · Guangxi Medical University (1) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (1) · University of California, San Diego (1) · University of Florida (1) · Xinqiao Hospital of Chongqing (1) · Zhejiang Cancer Hospital (1)
United States (4) · China (3) · Germany (2) · Czechia (1) · Italy (1)
Annalisa Trama, MD (1) · Assuntina Sacco, M.D. (1) · C. Jillian Tsai, MD (1) · Nancy Lee, MD (1) · Roi Dagan, MD, MS (1) · Udo Kontny, MD (1)